a_mahmoud

Inovio appoints ex-Merck vaccines president Dr Adel Mahmoud

pharmafile | March 29, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Inovio, Merck, vaccines 

Inovio Pharmaceuticals has announced that Dr Adel Mahmoud has been appointed to its Board of Directors. 

Mahmoud, a global infectious disease and vaccines expert, moves from Merck where he was responsible for the development and commercialisation of several new vaccines.

Mahmoud is currently Professor, Department of Molecular Biology and the Woodrow Wilson School of Public and International Affairs at Princeton University, US. He was President, Merck Vaccines, from 1999 to 2005 and also served as Merck’s chief medical advisor for vaccines and infectious diseases. 

More recently, Mahmoud has been leading strategy development for global health agencies tackling bioterrorism and emerging diseases such as pandemic influenza and SARS. Prior to joining Merck, Mahmoud was chairman, Department of Medicine and physician-in-chief (1987-1998) at Case Western Reserve University School of Medicine and University Hospitals of Cleveland.

Advertisement

Dr J. Joseph Kim, president and chief executive of Inovio said: “Dr Mahmoud is known throughout the industry for his success in gaining approval for several blockbuster vaccines.  His insights will be advantageous to Inovio as we move our synthetic vaccine portfolio toward late-stage clinical trials.”

Related Content

Valneva Scotland supports local cancer charity Team Jak Foundation 

Valneva Scotland, the country’s largest vaccine producer, has partnered with local West Lothian-headquartered charity, Team …

Vaccine image

Pfizer releases results for severe RSV-associated LRTD treatment study

US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …

acute_leukemia-all

Merck to acquire Curon Biopharmaceutical’s B-Cell Depletion Therapy

Merck have announced that they have entered into an agreement with private biotechnology company Curon …

The Gateway to Local Adoption Series

Latest content